Home›The Library›Leuprolide
Leuprolide (Lupron)
Leuprolide is the GnRH-axis drug that actually stayed in business. Approved in 1985 — around the same era as this site's gonadorelin page — it remains one of the most widely used hormone therapies in oncology, gynecology and pediatric endocrinology today, on real, large trial evidence, while gonadorelin's branded products were discontinued for commercial reasons. Same drug class, same era, very different fate.
On this page
In brief
Should you care? Yes if you've read this site's gonadorelin page — leuprolide is the same GnRH-axis mechanism from the same 1980s era, but still in wide, current clinical use rather than discontinued.The short version
- FDA-approved (1985) for palliative treatment of advanced prostate cancer — backed by a real randomized trial against the prior standard of care.
- Genuinely still in active, mainstream use across oncology, gynecology, and pediatric endocrinology today.
- A real, FDA-labeled safety issue — initial testosterone/estrogen "flare," and an increased diabetes/cardiovascular risk signal across GnRH agonists.
What it is, and its real 1985 approval
Leuprolide (leuprorelin) is a synthetic GnRH agonist. FDA approved it in 1985 for the palliative treatment of advanced (metastatic) prostate cancer, offering a chemical alternative to surgical castration or high-dose estrogen therapy. It's marketed as Lupron and Lupron Depot, among other brand names for other indications.
The pivotal trial evidence
The Leuprolide Study Group's randomized trial (N Engl J Med 1984;311:1281-1286, PMID 6436700) compared leuprolide against diethylstilbestrol (DES), the prior standard hormonal therapy, in 199 men with metastatic prostate cancer: 86% objective response with leuprolide versus 85% with DES — therapeutically equivalent — but with substantially less gynecomastia, thromboembolism, nausea and vomiting than DES. This is a real, controlled, comparative trial against the actual standard of care of its era.
Why it's still in wide use, unlike gonadorelin
Since 1985, leuprolide's approved uses have expanded to include endometriosis, uterine fibroids, central precocious puberty, and continued use across prostate and (in some formulations) breast cancer protocols — a genuinely broad, current, active prescribing base across oncology, reproductive endocrinology and pediatrics. That's the direct contrast with this site's gonadorelin page: both are 1980s-era GnRH-axis drugs, but gonadorelin's two branded products (Factrel, Lutrepulse) were discontinued for commercial reasons, while leuprolide never left the market and remains available as both branded depot formulations and generics.
A real, labeled flare effect
Because GnRH agonists initially stimulate the pituitary before suppressing it, leuprolide causes a transient testosterone (or estrogen) surge at treatment initiation — a real, FDA-labeled effect that can temporarily worsen prostate-cancer symptoms like bone pain, and is managed clinically with a short course of an anti-androgen in higher-risk patients.
A real safety chapter worth knowing
FDA has required updated labeling across GnRH agonists, including leuprolide, after a safety review found an increased risk of diabetes and certain cardiovascular events in men receiving these drugs for prostate cancer — a real, FDA-driven label update, not an unsubstantiated concern. Long-term use is also associated with bone-density loss. None of this is unique to leuprolide among GnRH agonists, but it's a genuine part of its risk profile worth stating plainly alongside its long, otherwise well-established track record.
References
- The Leuprolide Study Group, "Leuprolide versus diethylstilbestrol for metastatic prostate cancer," N Engl J Med 1984;311:1281-1286, PMID 6436700.
- FDA approval history of Lupron (leuprolide acetate), 1985, for advanced prostate cancer.
- FDA Drug Safety Communication regarding GnRH agonists (including leuprolide) and increased risk of diabetes and certain cardiovascular events.